AIM ImmunoTech

Today there is no realized pricing power because AIM has no marketed products. In a successful orphan oncology scenario, list pricing could be high relative to standard chemotherapy, but actual pricing latitude will be constrained by competition and real‑world outcomes.

The competitive bar rose with the August 26, 2026 FDA approval of daraxonrasib for previously treated metastatic pancreatic adenocarcinoma, which could narrow room for premium pricing unless Ampligen combinations show clear additive benefit. Score reflects hypothetical but unproven pricing ability.